A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

August 5, 2021

Study Completion Date

April 2, 2024

Conditions
Autoimmune Hemolytic Anemia
Interventions
DRUG

Parsaclisib

Parsaclisib administered orally.

Trial Locations (12)

10021

Weill Medical College of Cornell University, New York

10467

Montefiore Medical Center, The Bronx

20007

Georgetown University Hospital, Washington D.C.

20122

Fondazione Irccs Ca Granda Ospedale Maggiore, Milan

28100

AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARIT� DI NOVARA, Novara

37920

University Health System Inc., Dba the University of Tn Medical Center, Knoxville

55455

University of Minnesota, Minneapolis

59037

Centre Hospitalier Regional Universitaire (Chru) de Lille, Lille

63110

Washington University School of Medicine, St Louis

80131

UNIVERSIT� DI NAPOLI FEDERICO II, Napoli

94010

Centre Hospitalier Universitaire Henri Mondor, Créteil

01090

Allgemeines Krankenhaus Der Stadt Wien, Vienna

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY